EIKON THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
EIKON THERAPEUTICS, INC. (EIKN) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $37.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- EIKON THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $56.29M, a 31.24% decline year-over-year.
- EIKON THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $81.86M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month |
|---|---|---|
| 2026-06-30 | $37.79M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $56.29M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $13.77M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $81.86M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |